Nanjing Leads Biolabs (HKG:9887) will present a paper on its phase IIb study of its drug to treat a rare form of lung cancer, LBL-024, at this year's European Society for Medical Oncology annual meeting, according to a Monday filing with the bourse.
The biotech company said it was chosen to present three studies overall at the medical conference, reflecting the importance of its clinical research in treating patients with advanced extrapulmonary neuroendocrine carcinoma.
Shares were down 3% in recent trading on Tuesday.